Baxalta Incorporated, a leading biopharmaceutical company, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2015, Baxalta emerged from a spin-off of Baxter International, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its specialised products in haemophilia, immunology, and oncology, with offerings such as Adynovate, a unique recombinant factor VIII therapy that enhances patient outcomes. Baxalta has established a strong market position, recognised for its commitment to research and development, which has led to significant advancements in treatment options. With a dedication to improving patient lives, Baxalta continues to be a key player in the biopharmaceutical industry, striving for excellence in every aspect of its operations.
We don't have data for Baxalta Incorporated, but we can show you information about their parent organization instead.
View parent company